In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission

Journal of Clinical Oncology

Volumn 14, Issue 8, 1996, Pages 2206-2216

  Stein, A S ^a   O'Donnell, M R ^a   Chai, A ^a   Schmidt, G M ^a   Nademanee, A ^a   Parker, P M ^a   Smith, E P ^a   Snyder, D S ^a   Molina, A ^a   Stepan, D E ^a   Spielberger, R ^a   Somlo, G ^a   Margolin, K A ^a   Vora, N ^a   Lipsett, J ^a   Lee, J ^a   Niland, J ^a   Forman, S J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW TOXICITY; BRAIN TOXICITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEPSIS; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 9444289886     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.8.2206     Document Type: Article

References (54)

1. Preisler H, Raza A, Larson R, et al: Some reasons for the lack of progress in the treatment of acute myelogenous leukemia: A review of three consecutive trials of the treatment of poor prognosis patients. Leuk Res 15:773-780, 1991
2. Estey E, Thall PF, Kantarjian H, et al: Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose Ara-C + daunorubicin: Comparison to patients treated without GM-CSF. Blood 79:2246-2255, 1992
3. Mastrianni DM, Tung NM, Tenen DG: Acute myelogenous leukemia: Current treatment and future directions. Am J Med 92:286-295, 1992
4. Phillips GL, Reece DE, Shepherd JD, et al: High-dose cytarabine and daunorubicin induction and post remission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood 77:1429-1435, 1991
5. Berman E, Heller G, Santorsa J, et al: Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77:1666-1674, 1991
6. Schiller G, Gajewski J, Territo M, et al: Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 80:2977-2982, 1992
7. Curtis JE, Messner HA, Minden MD, et al: High-dose cytosine arabinoside remission induction for acute myelogenous leukemia: Comparison of two regimens of remission maintenance. Leukemia 6:1192-1198, 1992
8. Mitus JA, Miller KB, Schenkein DP, et al: Improved survival for patients with acute myelogenous leukemia. J Clin Oncol 13:560-569, 1995
9. Cassileth PA, Harrington DP, Hines JD, et al: Maintenance chemotherapy prolongs remission duration in adult acute non-lymphocytic leukemia. J Clin Oncol 6:583-587, 1988
10. Embury SH, Elias L, Heller PH, et al: Remission maintenance therapy in acute myelogenous leukemia. West J Med 126:267-272, 1977
11. Cassileth PA, Lynch E, Hines JD, et al: Varying intensity of post-remission therapy in acute myeloid leukemia. Blood 79:1924-1930, 1992
12. Geller RB: Post-remission therapy of acute myelocytic leukemia in adults: Curability breeds controversy. Leukemia 6:915-925, 1992
13. Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896-903, 1994
14. Snyder DS, Chao NJ, Amylon MD, et al: Fractionated total body irradiation high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. Blood 82:2920-2928, 1993
15. Thomas ED, Buckner CD, Clift RA, et al: Marrow transplantation for acute non lymphoblastic leukemia in first remission. N Engl J Med 301:597-599, 1979
16. McGlave PB, Haake RJ, Bostrom BC, et al: Allogeneic bone marrow transplantation for acute non-lymphocytic leukemia in first remission. Blood 72:1512-1517, 1988
17. Zwaan FE, Hermans J, Barrett AJ, et al: Bone Marrow transplantation for acute non-lymphoblastic leukemia: A survey of the European Group for Bone Marrow Transplantation (E.G.B.M.T.). Br J Haematol 56:645-653, 1984
18. Sullivan KM, Agura E, Anasetti C, et al: Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 28:250-259, 1991
19. Gale R, Champlin R: How does bone-marrow transplantation cure leukemia? Lancet 2:28-29, 1984
20. Brenner MK, Rill DR, Moen RC, et al: Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 341:85-86, 1993
21. Stein AS, Nademanee A, O'Donnell MR, et al: High dose cytosine arabinoside and daunorubicin for induction therapy of AML: Results for 100 consecutively treated patients. Blood 76:323a, 1990 (suppl 1, abstr 1283)
22. Willman CL, Kopecky KJ, Weick J, et al: Biologic parameters that predict treatment response in de novo acute myeloid leukemia (AML): CD34, but not multidrug resistance (MDR) gene expression, is associated with a decreased complete remission (CR) rate and CD34+ patients more frequently achieve CR with high dose cytosine arabinoside. Proc Am Soc Clin Oncol 11:262, 1992 (abstr 85)
23. Cheson B, Cassileth PA, Head DR, et al: Report of National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813-819, 1990
24. Samuels BL, Larson RA, Le Beau MM, et al: Specific chromosomal abnormalities in acute non-lymphocytic leukemia correlate with drug susceptibility in vivo. Leukemia 2:79-83, 1988
25. Schiffer CA, Lee EJ, Tomiyasu R, et al: Prognostic impact of cytogenetic abnormalities in patients with de novo acute non-lymphocytic leukemia. Blood 73:263-270, 1989
26. Damon LE, Mass R, Linker CA: The association between high dose cytarabine neurotoxicity and renal insufficiency. J Clin Oncol 7:1563-1568, 1989
27. Blume KG, Forman SJ, O'Donnell MR, et al: Total body irradiation and high-dose etoposide: A new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 69:1015-1020, 1987
28. Stiff PJ, Koester AR, Weidner MK, et al: Autologous bone marrow transplantation using unfractionated cells cryopreserved in dimethylsulfoxide and hydroxy ethyl starch without controlled-rate freezing. Blood 70:974-978, 1987
29. O'Donnell MR, Schmidt GM, Tegtmeier BR, et al: Prediction of systemic fungal infection in allogeneic marrow recipients: Impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol 12:827-834, 1994
30. Kaplan G, Meier P: Non-parametric estimations from incomplete observations. J Am Stat Assoc 53:457-481, 1958
31. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
32. Linker CA, Ries CA, Damon LE, et al: Autologous bone marrow transplantation for acute myeloid leukemia using busulfan and etoposide as a preparative regimen. Blood 81:311-318, 1993
33. Chao NJ, Stein AS, Long GD, et al: Busulfan/etoposide-Initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. Blood 81:319-323, 1993
34. Cassileth PA, Andersen J, Lazarus HM, et al: Autologous bone marrow transplant in acute myeloid leukemia in first remission. J Clin Oncol 11:314-319, 1993
35. Gorin NC, Aegerter P, Auvert B, et al: Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: A European survey of the role of marrow purging. Blood 75:1606-1614, 1990
36. Korbling M, Fliedner TM, Holle R, et al: Autologous blood stem cell (ABSCT) versus purged bone marrow transplantation (pABMT) in standard risk AML: Influence of source and cell composition of the autograft on hemopoietic reconstitution and disease-free survival. Bone Marrow Transplant 7:343-349, 1991
37. McMillan AK, Goldstone AH, Linch DC, et al: High-dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia. Blood 76:480-488, 1990
38. Ball ED, Mills LE, Cornwell GG III, et al: Autologous bone marrow transplantation for acute myeloid leukemia using monoclonal antibody-purged bone marrow. Blood 75:1199-1206, 1990
39. Lowenberg B, Verdonck LJ, Dekker AW, et al: Autologous bone marrow transplantation in acute myeloid leukemia in first remission: Results of a Dutch prospective study. J Clin Oncol 8:287-294, 1990
40. Stewart P, Buckner CD, Bensinger W, et al: Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia in first remission. Exp Hematol 13:267-272, 1985
41. Yeager AM, Kaizer H, Santos GW, et al: Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophos-phamide. N Engl J Med 315:141-147, 1986
42. Korbling M, Hunstein W, Fliedner TM, et al: Disease-free survival after autologous bone marrow transplantation in patients with acute myelogenous leukemia. Blood 74:1898-1904, 1989
43. Beelen DW, Quabeck K, Graeven U, et al: Acute toxicity and first clinical results of intensive post induction therapy using a modified busulfan and cyclophosphamide regimen with autologous bone marrow rescue in first remission of acute myeloid leukemia. Blood 74:1507-1516, 1989
44. Freedman AS, Ritz J, Neuberg D, et al: Autologous bone marrow transplantation in 69 patients with a history of low grade B cell non-Hodgkin's lymphoma. Blood 77:2524-2529, 1991
45. Freedman AS, Nadler LM: Which patients with relapsed non-Hodgkin's lymphoma benefit from high-dose therapy and hematopoietic stem-cell transplantation. J Clin Oncol 11:1841-1843, 1993
46. Dutcher JP, Schiffer CA, Wiernik PH: Hyperleukocytosis in adult acute nonlymphocytic leukemia: Impact on remission rate and duration, and survival. J Clin Oncol 5:1364-1372, 1987
47. Zittoun R, Mandelli F, Willemze R, et al: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 332:217-223, 1995
48. Jones RJ, Vogelsang GB, Hess AD, et al: Induction of graftversus-host disease after autologous bone marrow transplantation. Lancet 1:754-757, 1990
49. Fefer A, Benyunes MC, Massumoto C, et al: Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies. Semin Oncol 20:41-44, 1993 (suppl 9)
50. Charak BS, Byrnes RK, Croshen S, et al: A bone marrow transplantation with interleukin-2 activated bone marrow followed by interleukin-2 therapy for acute myeloid leukemia in mice. Blood 76:2187-2190, 1990
51. UcKun FM, Kim TH, Ramsay NC, et al: Radiobiological heterogeneity of leukemic lymphocyte precursors from acute lymphoblastic leukemia patients. Int J Radiat Biol 56:611-615, 1989
52. Clift RA, Buckner D, Appelbaum FR, et al: Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: A randomized trial of two irradiation regimens. Blood 77:1660-1665, 1991
53. Appelbaum FR, Matthews DC, Eary JF, et al: The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 54:829-833, 1992
54. Matthews DC, Appelbaum FR, Eary JF, et al: Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 1131-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 85:1122-1131, 1995